When cancer patients are treated with anti-CTLA-4 antibodies, CD8+ T cells are released from their anergy state and attack tumor cells, but at the same time, CD8+ T cells also attack normal cells that present cross-reactive antigens. This evidence concerns the gene CTLA4 and neoplasm.